The Evolving Treatment Paradigm for Stage I-IIIB NSCLC

Emerging data continue to shape perioperative therapy decisions for patients with early-stage non–small cell lung cancer.

Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.